Stryker Corporation (NYSE:SYK) is one of the best healthcare AI stocks to buy now. On December 11, Citi cut the price target on Stryker Corporation (NYSE:SYK) from $455 to $420, while maintaining a Buy rating on the shares. This adjustment, the firm said, is part of a sector-wide adjustment as it formulates its 2026 outlook. Citi Cuts Stryker (SYK) PT, Maintains Buy Amid Leadership Changes Independently of the analyst action, on December 11, Stryker’s Board of Directors declared a $0.88 per share quarter ...

Funding a med-tech company isn’t for VCs who want quick returns.Gabriel Sanchez, co-founder of @enspectra, joins us on Build Mode to talk about how you keep a company afloat when it could be 10 years before your product is able to hit the market.Listen to the full episode here: https://t.co/i6TUbAZCki ...

Insulet Corporation (NASDAQ:PODD) is one of the best growth stocks to buy in 2026. On December 18, Truist lowered the firm’s price target on Insulet to $390 from $412 with a Buy rating on the shares. This sentiment was posted as part of the firm’s broader research note that previewed 2026 for MedTech. Truist expressed a more positive outlook on the healthcare sector for 2026 due to increasingly attractive relative valuations. However, the firm cautioned that the sector might act as a source of funds rather ...

Core Viewpoint - Optum Behavioral Health has expanded its medical policy to cover Deep TMS therapy for adolescents aged 15 and older with major depressive disorder, reflecting a growing recognition of this treatment as essential in modern mental health care [1][2]. Group 1: Coverage Expansion - Optum's policy expansion aligns with other insurers such as Evernorth Health Services, CVS/Aetna, and several Blue Cross and Blue Shield companies, collectively covering approximately 180 million lives [2]. - The inclusion of adolescents in the coverage for Deep TMS therapy signifies a commitment to early intervention and innovation in treating major depressive disorder [2]. Group 2: Public Health Challenge - An estimated 5 million adolescents aged 15–21 in the U.S. experience major depression, which disrupts developmental milestones and can lead to higher healthcare costs and comorbid conditions [3]. - The limited treatment options for adolescents who cannot tolerate or do not respond to medication highlight a critical gap in access to effective treatments for this vulnerable population [3]. Group 3: Deep TMS Technology - BrainsWay's Deep TMS is FDA cleared as an adjunct therapy for adolescents with depression, demonstrating meaningful response and remission rates [4]. - The company utilizes proprietary H-coil technology and is committed to expanding access to advanced neurostimulation therapies through ongoing clinical research and collaboration with providers [4][5]. Group 4: Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, with FDA-cleared indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5]. - The company was founded in 2003 and operates in the U.S. and Israel, focusing on increasing global awareness and access to Deep TMS technology [5].

Core Viewpoint - The company, Yahua Electronics, is focusing on the integration of its smart communication systems for hospital wards with brain-computer interface (BCI) technology, aiming to innovate in medical and care scenarios through technological advancements [1] Group 1: Company Developments - Yahua Electronics has announced its smart communication interactive system for hospital wards can achieve preliminary integration with brain-computer interface (BCI) technology [1] - The company is dedicated to the research and development of smart communication systems in hospitals, emphasizing the application of new technologies such as BCI, IoT, and AI in medical and care environments [1]

Funding a med-tech company isn’t for VCs who want quick returns.Gabriel Sanchez, co-founder of @enspectra, joins us on Build Mode to talk about how you keep a company afloat when it could be 10 years before your product is able to hit the market.Listen to the full episode here: https://t.co/i6TUbAZCki ...

Core Insights - Companies like Brookfield Renewable, Realty Income, and Medtronic are expected to continue increasing their dividends in 2026, supported by strong financial performance and growth strategies [1][16]. Brookfield Renewable - Brookfield Renewable currently has a dividend yield of 4% and has increased its dividend by at least 5% annually for the past 14 years, with expectations of 5% to 9% growth in the coming years [4][7]. - The company benefits from a stable cash flow generated by long-term fixed-rate contracts with inflation-linked rate escalations, which supports its dividend growth [5]. - Brookfield has a robust pipeline of development projects and acquisitions, aiming for over 10% annual growth in funds from operations (FFO) [7]. Realty Income - Realty Income offers a monthly dividend with a current yield of 5.7% and has a strong history of increasing its payout, having raised it 133 times since 1994, including 113 consecutive quarters [8][10]. - The REIT maintains a conservative dividend payout ratio of around 75% of adjusted FFO, generating approximately $850 million in free cash flow annually for reinvestment [10]. - Realty Income has diversified its investment platform, with significant investments in Europe due to higher initial cash yields, and continues to find attractive opportunities to support future dividend increases [11]. Medtronic - Medtronic has a dividend yield of 2.9% and has increased its dividend for 48 consecutive years, demonstrating a strong commitment to returning value to shareholders [12][14]. - The company generated $7 billion in cash from operations and $5.2 billion in free cash flow in the last fiscal year, returning $6.3 billion to shareholders through dividends and stock repurchases [14]. - Despite facing some headwinds that may slow earnings-per-share growth to around 1% this fiscal year, Medtronic anticipates high-single-digit growth in fiscal 2027 as these challenges subside [15].

(a) the publication of this announcement on the Stock Exchange's website does not give rise to any obligation of the Company, its joint sponsors, sponsor-overall coordinator, overall coordinators, advisors or members of the underwriting syndicate to proceed with an offering or a placing in Hong Kong or any other jurisdiction. There is no assurance that the Company will proceed with the offering or the placing; (b) the application to which this announcement relates has not been approved for listing and the S ...

Core Insights - Lifeward Ltd. has appointed Bob Marshall as the new Chairman of the Board, effective January 1, 2026, succeeding Joseph Turk who is transitioning to a new role at Fresenius Medical Care [1][2] Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [3] - The company designs, develops, and commercializes solutions for physical rehabilitation and recovery, with a mission to drive innovation for individuals with disabilities [3] - Lifeward's product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System [3] - Founded in 2001, Lifeward operates in the United States, Israel, and Germany [3] Leadership Changes - Bob Marshall has been a member of Lifeward's Board and Chair of the Audit Committee since 2024, bringing financial leadership and healthcare expertise to the role [2] - Prior to joining Lifeward, Bob Marshall served as Chief Financial Officer and Treasurer of Lantheus Holdings since 2018 and held various positions at Zimmer Biomet Holdings [2]

Core Insights - IBA has acquired ORA, a leader in radiochemistry, enhancing its position in the nuclear medicine sector [1][2] - The acquisition aims to integrate IBA's cyclotron technology with ORA's advanced solutions, providing competitive offerings for hospitals and radiopharmacy networks [3] - This move aligns with IBA's strategic initiatives in nuclear medicine, including partnerships for isotope production and innovation in patient care [4] Financial Aspects - The acquisition is valued between €15-20 million on a cash-free, debt-free basis and is expected to be immediately accretive to IBA's revenue and EBITDA [5] - The transaction will be financed through IBA's own funds and existing credit facilities, with no material impact on IBA's 2025 financial guidance [5] Company Profiles - IBA is a global leader in particle accelerator technology, specializing in proton therapy, industrial sterilization, and radiopharmaceuticals, employing approximately 2,100 people [7] - ORA Group is recognized for its automated PET radiopharmaceutical synthesizers, contributing to the production of sterile injectable PET drug products [8]